Alembic Pharmaceuticals' latest updates

Alembic Pharmaceuticals has reported its Q1 FY2026 financial highlights, with net sales increasing by 2.95% to ₹1,561.73 crore. However, net profit for the quarter saw a significant year-on-year decrease of 24.60% to ₹134.37 crore. This follows their Q4 FY2025 results where net sales increased, but net profit had also seen a dip. In a significant move to bolster its US branded portfolio, Alembic Pharmaceuticals Inc., a wholly-owned subsidiary, has acquired Utility Therapeutics for approximately $12 million. This acquisition brings FDA-approved products like "Pivya" for uncomplicated urinary tract infections (UTIs) and "MEC," a product in development for complicated UTIs, strengthening Alembic's presence in the US market. Alembic recently received final USFDA approval for its generic Doxorubicin Hydrochloride Liposome Injection, a crucial drug for treating various cancers including ovarian cancer and AIDS-related Kaposi's sarcoma. This approval, coupled with an Establishment Inspection Report (EIR) from the USFDA for its API-III facility in Karakhadi, underlines their ongoing regulatory compliance and growing US generics pipeline. The company has also announced a final dividend of ₹11.0 per share for the financial year ended March 31, 2025. The record date for determining eligible shareholders is July 29, 2025, with payment expected on or after August 7, 2025, upon approval at the Annual General Meeting.